Teva- Pharmaceutical Industries Ltd. TEVA

NYS: TEVA | ISIN: US8816242098   7/07/2025
16,85 USD (-0,94%)
(-0,94%)   7/07/2025
Bedrijfsnieuws uit Amerika

Bedrijfsnieuws uit Amerika · Bolero.be

Politieke ambities van CEO Musk negatief voor Tesla De fabrikant van elektrische voertuigen daalde nadat CEO Elon Musk aankondigde een nieuwe politieke partij op te richten, genaamd de “America Party.” Musk ligt in de clinch...

26 juni 2025 · Teva Releases Q2 2025 Aide Memoire · Persbericht

25 juni 2025 · Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025 · Persbericht

24 juni 2025 · Les données définitives de l’étude PEARL menée par Teva en conditions réelles confirment l’efficacité à long terme d’AJOVY® (frémanézumab) pour la prévention de la migraine chronique et épisodique · Persbericht

23 juni 2025 · Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine · Persbericht

16 juni 2025 · Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology · Persbericht

3 juni 2025 · Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer · Persbericht

3 juni 2025 · Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement · Persbericht

31 mei 2025 · New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025 · Persbericht

31 mei 2025 · Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date · Persbericht

29 mei 2025 · Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day · Persbericht

27 mei 2025 · Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA · Persbericht

27 mei 2025 · Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June · Persbericht

27 mei 2025 · Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma · Persbericht

22 mei 2025 · Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes · Persbericht

20 mei 2025 · Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt · Persbericht

20 mei 2025 · Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy · Persbericht

19 mei 2025 · Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031 · Persbericht

19 mei 2025 · Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes · Persbericht

16 mei 2025 · Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy · Persbericht

Mijn selecties